Vericel (NASDAQ: VCEL)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-03 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.120 | -0.150 | -0.0300 | ||||
REV | 34.310M | 36.074M | 1.764M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Vericel (NASDAQ: VCEL) through any online brokerage.
Other companies in Vericel’s space includes: Chinook Therapeutics (NASDAQ:KDNY), Syndax Pharmaceuticals (NASDAQ:SNDX), Arcutis Biotherapeutics (NASDAQ:ARQT), FibroGen (NASDAQ:FGEN) and Prothena Corp (NASDAQ:PRTA).
The latest price target for Vericel (NASDAQ: VCEL) was reported by SVB Leerink on Friday, February 25, 2022. The analyst firm set a price target for 45.00 expecting VCEL to rise to within 12 months (a possible 75.10% upside). 3 analyst firms have reported ratings in the last year.
The stock price for Vericel (NASDAQ: VCEL) is $25.7 last updated June 24, 2022, 8:00 PM UTC.
There are no upcoming dividends for Vericel.
Vericel’s Q2 earnings are confirmed for Wednesday, August 3, 2022.
There is no upcoming split for Vericel.
Vericel is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.